Entrada Therapeutics Inc (TRDA)
NASDAQ:TRDA
Want to see TRDA full AI Analyst Report?
Top Page
Entrada Therapeutics Inc
(NASDAQ:TRDA)
Select Model
Select Model
Rating:46Neutral
Price Target:
$6.50
▼(-53.54% Downside)
Action:Reiterated
Date:05/19/26
The score is held down primarily by sharply deteriorating financial performance (large losses and significant cash burn) and a clearly bearish technical setup with the stock far below key moving averages. Positive corporate updates and reported clinical progress provide some offset, but do not fully counterbalance the near-term financial and trend risks.
Positive Factors
Platform & Broad Clinical Pipeline
Entrada's proprietary intracellular delivery platform underpins multiple clinical-stage programs across Duchenne, myotonic dystrophy and inherited retinal diseases. This diversified pipeline and a Vertex-partnered program provide structural validation and reduce binary risk versus a single asset, supporting sustained R&D optionality and partner interest.
Negative Factors
High Cash Burn
Sustained negative operating and free cash flows on the order of ~$132M TTM create a structural funding challenge: continued burn will erode runway absent new capital or material revenue, forcing dilution, partnership concessions, or program prioritization decisions that can delay or derail long-term development plans.
Read all positive and negative factors
Positive Factors
Negative Factors
Platform & Broad Clinical Pipeline
Entrada's proprietary intracellular delivery platform underpins multiple clinical-stage programs across Duchenne, myotonic dystrophy and inherited retinal diseases. This diversified pipeline and a Vertex-partnered program provide structural validation and reduce binary risk versus a single asset, supporting sustained R&D optionality and partner interest.
Read all positive factors
Entrada Therapeutics Inc (TRDA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$244.96M
Dividend YieldN/A
Average Volume (3M)490.75K
Price to Earnings (P/E)―
Beta (1Y)1.16
Revenue Growth-96.67%
EPS Growth-559.52%
CountryUS
Employees183
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.00
Shares Outstanding38,820,618
10 Day Avg. Volume1,051,019
30 Day Avg. Volume490,745
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.39
Price to Sales (P/S)16.73
P/FCF Ratio-3.28
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue39.73
Enterprise Value/Gross Profit-6.64
Enterprise Value/Ebitda-1.33
Forecast
1Y Price Target
$19.50Price Target Upside39.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-3.96
Revenue Forecast (FY)$19.40M
Entrada Therapeutics Inc Business Overview & Revenue Model
Company Description
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody...
How the Company Makes Money
Entrada Therapeutics is a clinical-stage biotech company and does not primarily generate recurring product sales because it does not have approved commercial products. The company’s funding and revenue, when present, generally come from a combinat...
Entrada Therapeutics Inc Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
66
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.74M | 25.42M | 210.78M | 129.01M | 0.00 | 0.00 |
| Gross Profit | -34.31M | 21.32M | 210.78M | 129.01M | 0.00 | 0.00 |
| EBITDA | -171.42M | -142.40M | 47.01M | -321.00K | -95.35M | -50.01M |
| Net Income | -166.12M | -143.75M | 65.63M | -6.68M | -94.62M | -51.16M |
Balance Sheet | ||||||
| Total Assets | 335.52M | 377.38M | 526.32M | 469.19M | 252.06M | 305.83M |
| Cash, Cash Equivalents and Short-Term Investments | 254.86M | 295.70M | 420.00M | 351.97M | 188.71M | 291.06M |
| Total Debt | 49.75M | 50.93M | 59.21M | 68.23M | 25.94M | 0.00 |
| Total Liabilities | 64.66M | 71.25M | 97.64M | 226.83M | 39.50M | 7.12M |
| Stockholders Equity | 270.85M | 306.13M | 428.68M | 242.36M | 212.55M | 298.72M |
Cash Flow | ||||||
| Free Cash Flow | -131.64M | -129.55M | -44.72M | 134.19M | -96.67M | -55.44M |
| Operating Cash Flow | -131.70M | -128.51M | -41.56M | 139.80M | -93.79M | -50.86M |
| Investing Cash Flow | 139.01M | 116.81M | -27.80M | -138.40M | -148.65M | -4.58M |
| Financing Cash Flow | 637.00K | 887.00K | 102.96M | 21.04M | 479.00K | 307.46M |
Entrada Therapeutics Inc Technical Analysis
Negative
13.99
Price Trends
11.61
Negative
11.43
Negative
9.34
Negative
Market Momentum
-1.88
Positive
32.20
Neutral
35.63
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TRDA, the sentiment is Negative. The current price of 13.99 is above the 20-day moving average (MA) of 9.65, above the 50-day MA of 11.61, and above the 200-day MA of 9.34, indicating a bearish trend. The MACD of -1.88 indicates Positive momentum. The RSI at 32.20 is Neutral, neither overbought nor oversold. The STOCH value of 35.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TRDA.
Entrada Therapeutics Inc Risk Analysis
Entrada Therapeutics Inc disclosed 93 risk factors in its most recent earnings report. Entrada Therapeutics Inc reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Entrada Therapeutics Inc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $428.29M | -4.00 | -37.57% | ― | ― | 24.50% | |
54 Neutral | $389.20M | -3.30 | -50.68% | ― | -12.37% | 19.59% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $203.42M | -3.37 | -36.37% | ― | -100.00% | -1056.82% | |
46 Neutral | $244.96M | -3.32 | -51.22% | ― | -96.67% | -559.52% |
* Healthcare Sector Average
TRDA
Entrada Therapeutics Inc
6.56
-0.94
-12.53%
BDTX
Black Diamond Therapeutics
2.28
0.27
13.43%
CCCC
C4 Therapeutics
3.56
2.18
157.97%
SGMT
Sagimet Biosciences, Inc. Class A
7.09
3.64
105.51%
Entrada Therapeutics Inc Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
Entrada Therapeutics Highlights Transformational Year and Pipeline Progress
Positive
May 19, 2026
On May 18, 2026, Entrada Therapeutics updated its corporate presentation to highlight what it calls a transformational year, underscored by five clinical-stage programs in Duchenne muscular dystrophy and myotonic dystrophy type 1 and a deepening p...
Business Operations and StrategyFinancial Disclosures
Entrada posts strong ENTR-601-44 Duchenne Phase 1/2 data
Positive
May 7, 2026
On May 7, 2026, Entrada Therapeutics reported first-quarter 2026 results and unveiled positive topline data from Cohort 1 of its Phase 1/2 ELEVATE-44-201 trial of ENTR-601-44 in boys with Duchenne muscular dystrophy amenable to exon 44 skipping. P...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.